ClinicalTrials.gg
CompletedNCT06167889Updated Dec 13, 2023

A Study of Gender-specific Impact Factors on Elderly Disability and Cognitive Impairment

An observational study in Aging, sponsored by Fang Tang. Completed at 1 site in China. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2023-12-13.

Sponsored by Fang Tang · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
23,640
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 310 studies in Cognitive Dysfunction with a site in China — 144 open to participants now, 156 under way, 8 of them phase 3. Cognitive Dysfunction · China.

Enrollment
2nd of 119
23,640 · median 300
Started
2009
with 1 other
Observational
119 of 310
64 open now
Registered
168th of 310
by date

Among the 310 studies in Cognitive Dysfunction with a site in China, this one is the 2nd largest by enrollment of the 119 observational ones that give a count, is one of 2 that started in 2009, is one of 119 observational ones, and was the 168th registered.

Cognitive Dysfunction

3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.

Browse Cognitive Dysfunction studies →

Open to participants now

144 of the 310 studies in Cognitive Dysfunction with a site in China are open now. Recruiting first, the newest first:

139 more — sign in →

All 144 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 310 studies in Cognitive Dysfunction with a site in China, or all of them as a file.
02

Study summary

Elderly disability and cognitive impairment rates were different between elderly man and woman. Sex-specific risk factors and observed gender differences across the lifespan were associated with different degrees of cognitive and activity of daily living function decline between men and women. However, some of these viewpoint remains controversial.

The aim of this study is to explore the gender differences and influencing factors of disability and cognitive impairment among the elderly.

Read the detailed description

With the rapid increase in the aging population in China, age-related cognitive impairment and disability has become a pressing public health concern. A number of large-scale studies in China and abroad have shown that the average life expectancy of women elderly is higher than men, but the rates of disability and cognitive impairment are higher. However, it is lack of exploration of the factors associated with the gender-specific of disability and cognitive impairment.

The aim of this study is to explore the gender differences and influencing factors of disability and cognitive impairment among the elderly. A retrospective cohort based on Shandong Provincial Qianfoshan Hospital Healthcare Big Data Platform is conducted to collect data. And the data from the China Longitudinal Healthy Longevity Survey (CLHLS) was used to further validate the results.

03

Conditions studied

  • Aging

Keywords

  • Elderly
  • Disability
  • Cognitive impairment
  • Gender-specific
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The elderly aged 65 and above in the China Longitudinal Healthy Longevity Survey (CLHLS) database and the elderly with health care neurology visits recorded in Shandong Provincial Qianfoshan Hospital Healthcare Big Data Platform

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

1.The elderly aged 65 and above.

Exclusion criteria

Exclusion Criteria:

  1. Lack of diagnostic information.
  2. Missing key influencing factors such as gender and age.
  3. Hearing or linguistic impairment.
  4. Comatose patients.
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
23,640 participants (actual)
Patient registry
No

Groups and cohorts

  • Retrospective cohort based on Shandong Provincial Qianfoshan Hospital Healthcare Big Data Platform

    A retrospective cohort based on Shandong Provincial Qianfoshan Hospital Healthcare Big Data Platform is conducted to collect data and to explore the gender differences and influencing factors of disability and cognitive impairment among the elderly.

  • Retrospective cohort from CLHLS

    The data from the China Longitudinal Healthy Longevity Survey (CLHLS) was used to further validate the results.

06

What researchers measure

Primary outcomes

  1. Disability

    We identified disability according to the Katz index. This Katz index includes six activities of daily life: bathing, transferring, dressing, eating, toileting, and continence. Disability was defined as needing help with at least one of the six activities of daily life.

    Time frame: 2002-2023

  2. Cognitive impairment

    The main outcome was assessed by the Chinese version of the Mini-Mental State Examination (CMMSE).For participants who had never received education, an MMSE score of 17 or less was considered as cognitive impairment; for those who had less than 6 years of education, an MMSE score of 20 or less was considered as cognitive impairment; and for those who had more than 6 years of education, an MMSE score of 24 or less was considered as cognitive impairment. For each level of education, scores above the threshold were considered cognitively normal.

    Time frame: 2002-2023

07

Study locations

1 site
  • The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital
    Jinan, Shandong 250014, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2009 to primary completion in Oct 2023, 177 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2023
First posted
Dec 13, 2023
StartActual
Jan 1, 2009
Primary completionActual
Oct 31, 2023
CompletionActual
Oct 31, 2023
Last update
Dec 13, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 13, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06167889
Lead sponsor
Fang Tang
Responsible party
Fang Tang (Doctor, Qianfoshan Hospital) — Sponsor-investigator
First posted
Dec 13, 2023
Start date
Jan 1, 2009
Primary completion
Oct 31, 2023
Completion
Oct 31, 2023
Last update
Dec 13, 2023

Study contacts

Fang Tang, Doctor
principal investigator · The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion